United States Federal Circuit

ResetAA Font size: Print

Gilead Sciences, Inc. v. Merck & Co., Inc., 16-2302

Affirming the judgment that Merck, initially defending its patent on Hepatitis C drugs against a competitor seeking to have them found invalid, who successfully counter-sued for infringement, had unclean hands regarding the patents and was properly barred from asserting its patents and awarded attorney fees to the plaintiff.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2018/04/25




  • United States Federal Circuit


FindLaw Career Center

    Select a Job Title

      Post a Job  |  Careers Home

    View More